Stroke Study to Begin in Denmark

Stroke Study to Begin in Denmark

Stem Cell Therapeutics Corp., which is based in Calgary, Canada and Medicon A/S of Birkerod, Denmark announced today that they have received approval to begin the Phase I Clinical Study in SCT's NTx-265 program for the treatment of stroke. The press release says that the study will begin in the “near future,” with a duration of eight weeks.

NTx-265 is not actually derived from stem cells. Instead, it is a pharmacological combination of several agents which work to stimulate the body’s own production of stem cells. In an interview with the Wall Street Reporter (PDF) last January, Joseph Tucker, the CEO of Stem Cell Therapeutics, described the drug in more detail and how it works. It has already been approved for use in humans in other applications besides stroke.